Trial · NCT07881302
Effect of Ivabradine on Adolescent Dysautonomia
NCT07881302, Phase 2, Not yet recruiting, Kathryn Armstrong
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Ivabradine on Adolescent Dysautonomia. Trials, record NCT07881302. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07881302
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Ivabradine on Adolescent Dysautonomia
- NCT number
- NCT07881302
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 5 participants, estimated
- Lead sponsor
- Kathryn Armstrong
- Conditions
- Dysautonomia of Adolescence
- Interventions
- Ivabradine, Placebo
- First posted
- 2026-10-19
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Resting Heart Rate (bpm) at end of 4-week treatment period. | From baseline pre-treatment to the end of treatment at 4 weeks (28 days) | Heart rate will be measured (ECG testing) before and after each 4-week treatment period. A decrease of greater than or equal to 10 beats per minute after 4 weeks of drug treatment will be considered clinically significant. |
| Secondary | Change from Baseline in Symptom Burden at end of 4-week treatment period. | From baseline pre-treatment to the end of treatment at 4 weeks (28 days) | Participants will identify 5 symptoms from a pre-defined list that are most disruptive to their day-to-day functioning. Individual symptoms will be rated for their frequency and severity using a 5-point Likert Scale from 0 = never or almost never have the symptom, to 4 = frequently have it, effect is severe. A decrease of 1 or more point on the Likert scale for 2 or more symptoms will be considered a meaningful response. |
| Secondary | Change from Baseline in Quality of Life Score as assessed by the PedsQL 4.0 at end of 4-week treatment period. | From baseline pre-treatment to the end of treatment at 4 weeks (28 days) | Quality of Life Score will be assessed using the Pediatric Quality of Life Inventory (PedsQL 4.0) questionnaire. Scores are on a scale of 0-100, where higher scores indicate a higher quality of life. An increase of 5 or more points in QoL Score will be considered clinically meaningful. |
| Other | Change from Baseline in Resting Heart Rate (bpm) | From baseline pre-treatment to the end of treatment at 4 weeks (28 days) | Participants will measure and self-report resting heart rate daily during each 4-week treatment period. Baseline measurements will be established for 1 week prior to start of the first drug cycle. |
| Other | Change from Baseline in Resting Blood Pressure (mmHg) | From baseline pre-treatment to the end of treatment at 4 weeks (28 days) | Participants will measure and self-report resting blood pressure daily during each 4-week treatment period. Baseline measurements will be established for 1 week prior to start of the first drug cycle. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07881302
GET https://conductscience.org/api/trials/v1/NCT07881302/registered